Procalcitonin-Guided Antibiotic Therapy
The Clinical Question Addressed by This Comparative Effectiveness Review
This comparative effectiveness review attempted to address the key question listed on this slide:
Key Question: In selected populations of patients with suspected local or systemic infection, what are the effects of using procalcitonin measurement plus clinical criteria for infection to guide initiation, discontinuation or a change of antibiotic therapy, when compared with clinical criteria for infection alone on:
- Intermediate outcomes, such as initiation, discontinuation or change of antibiotic therapy, antibiotic usage, and length of stay?
- Health outcomes, such as morbidity, mortality, function, quality of life, and adverse events of antibiotic therapy (persistent or recurrent infection and antibiotic resistance)?
Keywords: antibiotic therapy | bacterial infection | clinical question | procalcitonin | key question
- Soni NJ, Samson DJ, Galaydick JL, et al. Procalcitonin-Guided Antibiotic Therapy. Comparative Effectiveness Review No. 78 (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10058-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC124-EF. Available at www.effectivehealthcare.ahrq.gov/procalcitonin.cfm.
Your slide tray is being processed.